A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
In an interview with MDLinx during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discusses results from a phase I clinical trial designed to evaluate the safety and activity of ibrutinib plus palbociclib in people with previously treated MCL.
In an interview during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discusses results from a phase I clinical trial designed to evaluate the safety and activity of ibrutinib plus palbociclib in people with previously treated MCL. A full link to the video of Dr. Martin discussing the trial can be found by clicking above or be seen on Healio.com.
The results are in and the first annual Pie-in-the-face event was a smashing success! We raised $3500 for the The Leukemia and Lymphoma Society as part of the 2016 Light The Night campaign.
Obviously the highlight of the event was Lymphoma Program Director, Dr. John Leonard receiving a pie in the face from his esteemed colleague Dr. Peter Martin. Look at that fakeout!
Asked about his pie throwing heroics after the event Dr. Martin said, “Sometimes this job requires us to make tough decisions, like should I throw the pie with my left hand or right hand? At first I was nervous about throwing a pie at my boss…just kidding, it was awesome.”
More pics of the event can be found here. Thanks to the Meyer Cancer Center & Englander Institute for Precision Medicine for organizing this event. Additional donations can be made on our Light the Night team page.
New Developments in Lymphoma 